Strand Therapeutics, co-founded by Darrell Irvine, Ron Weiss, and Weiss Lab alum Jacob Becraft, is targeting tumors for immunotherapy by "programming" mRNA to allow it to turn on only in specific cell types, at specific times, and in specific amounts. The approach aims to avoid the systemic toxic side effects that often accompany cancer therapies when they are delivered to off-target tissue. This spring, Strand will enroll patients in a clinical trial of using its cancer-hunting mRNA therapy to treat solid tumors. The trial will be the first time a programmable mRNA therapy is tested in people.